The real-world data (RWD) landscape is transforming; rapidly expanding beyond traditional claims and EHR data to include wearables, genomics, formulary intelligence, social determinants of health, and patient-reported outcomes. These new sources, when combined with advancements in tokenization, cloud-based architecture, and AI-powered analytics (including the emergence of Agentic AI), are unlocking new frontiers in clinical evidence generation.
This white paper explores how life sciences companies can evolve with the RWD ecosystem to generate more precise, predictive, and real-time real-world evidence (RWE). It outlines the strategies needed to scale innovation and ensure data remains fit-for-purpose in a fast-moving landscape.
Inside, you’ll learn how to:
- Leverage expanded RWD sources to support decision-making across the product life cycle
- Apply AI-powered predictive analytics to accelerate and scale evidence generation
- Build data-agnostic frameworks and partnerships that deliver agile, impactful RWE
- Navigate regulatory expectations with confidence and methodological rigor
- Enable cross-functional teams to drive integrated evidence generation and improve patient outcomes.
You’ll also discover how we helped a leading pharma organization by utilizing a multi-source data integration strategy to identify patients with a rare disease and support targeted intervention design.
If your organization is ready to harness the full potential of RWD, Axtria can help. Learn how our data-agnostic, analytics-driven approach empowers life sciences companies to transform data into actionable insights—and lead the next era of evidence-based innovation. Reach out to us at Axtria_RWE.HEOR.ES@Axtria.com.
.jpg?width=690&height=468&name=AI-ML-in-life-sciences%20(1).jpg)
